OSR Holdings and BCM Europe Execute $815 Million License Agreement for VXM01 Immunotherapy Platform

On April 29, 2026, OSR Holdings, Inc. and its subsidiary Vaximm AG entered into a Global Exclusive License Agreement with BCM Europe AG (BCME), the company's largest shareholder. Under the agreement, OSR grants BCME an exclusive worldwide license to develop and commercialize VXM01, an oral DNA-based cancer immunotherapy platform currently Phase-2b-ready for glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC). BCME is responsible for all development and commercialization costs and is obligated to pay OSR milestone payments of up to $815 million based on clinical, regulatory, and commercial achievements. The deal includes a royalty pass-through structure where BCME remits royalties to OSR after recovering certain investment returns. Additionally, OSR received an equity put option to require BCME to purchase up to $15 million of OSR common stock at $10.00 per share. To secure milestone obligations, BCME pledged approximately 9.97 million OSR shares as collateral. OSR also plans to acquire VXM01 intellectual property rights from Vaximm for $30 million.